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Objectives: Imiquimod is an immune responsemodifier that has demonstrated a good efficacy and relatively low
recurrenceratesincomparisontoothergenitalwarttreatmentmodalities. Theprimaryobjectiveofthisopen-label
study was to evaluate the effect on sustained clearance of treated lesions and the safety of patient-applied topical
imiquimod after laser therapy of external anogenital warts.
Methods: After laser treatment of visible external anogenital warts the ablated region(s) were treated with
imiquimod5%creamthreetimes/weekover12weeksbeginningwhenthewoundhealingprocesswascompleted,
followed by a six-month treatment-free observation period for the assessment of sustained clearance of treated
lesions.
Results: A total of 211 male and female patientswas enrolled in the study.After 12 weeks of treatment,65.4% of
allpatientsshowed sustainedclearance.Duringthetreatmentperiod,15patients(7.1%of211patients)presented
with recurrent warts in the treated areas, and 58 (27.5%) patients were excluded for other reasons. During
the six-month follow-up period, ten additional patients (7.3% of 138 patients) developed wart recurrences.The
application of imiquimod 5% cream was well tolerated. The number of patients with adverse events related to
studymedication declinedfromthefirstmonthof treatmentuntilthe endofthethirdmonth.Mostfrequently,mild
to moderate itching, burning, pain and erythema were reported.
Conclusions: After laser therapy and sufficient wound healing, administration of imiquimod 5% cream three
times/week appears to be safe and to reduce the incidence of wart recurrences.
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Anogenital infections with human papillomavirus
(HPV) represent the most frequent viral sexually
transmitted disease (STD) in young adults world-
wide. In the USA about one to two percent of
the sexually active population between 15–49
years of age develop anogenital warts as the pri-
mary clinical manifestation of HPV infection1.
Recommended treatments include patient applied
topical therapies (imiquimod 5% cream, podo-
phyllotoxin, interferon (IFN)) and ablative or
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Clinical study 79cytodestructive methods, which have all shown
good to moderate efficacy in removing genital
warts2. Most of the ablative treatment modalities
have the potential to be painful and are awkward
for the patient due to anaesthesia or repeated
therapeutic interventions to remove the entire
wart area. However, the major frustration is
considered to be the high incidence of wart
recurrences after successful primary treatment.
Recurrence rates, which have been documented
for ablative methods, vary between 20% with
surgical excision up to 50% with laser
therapy3. One reason postulated for frequent
wart recurrence is the lack of antiviral activity
with most of the recommended therapies. Thus,
only the wart itself is physically destroyed, while
the latent HPV in the surrounding tissue
remain present with the potential of reactiva-
tion4. Imiquimod and interferon are the only
medical treatments available that exhibit an anti-
viral activity: both drugs have demonstrated lower
recurrence rates compared to other therapies3.
Imiquimod is a more complete and natural
approach as it is known to induce several sub-
types of IFN-a and IFN-g, as well as a variety
of cytokines associated with Th1-cell-mediated
immunity.
Imiquimod (ALDARAÒ 5% cream, 3M
Pharmaceuticals, Borken, Germany), an imidazo-
quinolinamine derivate, is the first representative
of a new class of immune response modifiers with
potent antiviral and antitumor activity5,6. In the
primary treatment of external genital warts,
imiquimod 5% cream, applied three times/week
for a maximum of 16 weeks, has been shown to be
highly effective and safe7–9. The recurrence rate in
one study, with three times per week dosing and
a treatment-free follow-up period of 12 weeks,
was as low as 13%8.
It has been hypothesized that recurrence rates
after wart ablation may be reduced by an adjuvant
IFN therapy, enhancing the patient’s immune
response to viral infections. However, most study
results didn’t show consistent beneficial effects
with combination therapy10. This clinical study
was performed to determine whether a combina-
tion of laser therapy followed by imiquimod 5%
cream for 12 weeks would reduce the incidence
of recurrent warts after laser treatment.
METHODS
Study design
This was a phase IIIb, open-labelled, prospective,
multicenter study performed in 23 sites around
Germany. Investigators were recruited predomi-
nantly from university hospitals: dermatology
(n = 10), obstetrics and gynecology (n = 10),
urology (n = 2) and one center of laser therapy.
The primary objective of the study was to evaluate
the safety and sustained clearance after laser treat-
ment of anogenital warts as assessed by clinical
visual inspection. The safety population included
all patients who received at least one dose of study
drug.Theapprovaloflocalethicalcommittees was
obtained prior to starting the study and each
patient’s written consent was obtained prior to
enrollment. The study was conducted in accord-
ance with the Declaration of Helsinki and Good
Clinical Practice Guidelines (ICH-GCP).
Patients
Male and female patients with external anogenital
warts aged 18 years or older were eligible for the
study. The acetowhite area had to be less than
20 cm2, and warts had to be removed by laser irra-
diationwithinthreeweeks beforestudyenrolment
of the individual patient.
Patientswereexcludedfromparticipationinthe
study if they had undergone any previous treat-
ment with imiquimod; treatment with IFN,
IFN-inducers, immunomodulators, oral antiviral
drugs(withexceptionoforalacyclovirforsuppres-
sive or acutetherapy), topical antiviral drugsto the
wart site, cytotoxic drugs, other investigational
drugs, drugs known to have major organ toxicity,
chemical and/or surgical wart therapy within four
weeks prior to entering the study; or oral cortico-
steroids, inhaled corticosteroids more than
1000 mg/day,or any non-warttherapy to thewart
site (within two weeks of initiation visit). Addi-
tionally, females pregnant or breast feeding and
patients with inflammatory skin conditions or
patientswhorequiredconcomitanttopicaltherapy
within the wart area were excluded. Other
exclusion criteria were: a history of Bowenoid
Papulosis, organ transplantation or any unstable
medical condition.
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During the screening visit all visible external
condylomata acuminata (target wart area) were
removed by laser treatment. Internal warts
(vaginal, cervical, urethral, vesical or intra-anal)
were also removed but were not considered base-
line wartsand were notincludedin thesubsequent
evaluation procedures; patients with recurrences
oftheirinternalwartswereexcluded.Patientswho
were completelycleared oftheir baseline wartsand
demonstrated sufficient wound healing, entered
the treatment phase within 21 days after laser
therapy.Theywere instructedtoapplyimiquimod
5% cream to the ablated target wart area three
times/week before bedtime; the cream should
remain on the skin for 8 ± 2 hours.
During the 12 weeks treatment period, patients
returned to the investigator every four weeks for
clinical evaluation of recurrent warts in the ablated
area or new warts outside the target area, and for
safety assessment. Whenever recurrentwartsin the
target areawereobserved,thepatientdiscontinued
treatment and was withdrawn from the study. All
patients who completed 12 weeks of treatment
without wart recurrences entered the six-month
follow-up phase; at three months and six months
follow-up, patients were assessed for recurrent
and/or new warts.
Assessment of efficacy and safety parameters
The primary efficacy parameter was the observed
sustained clearance rate of the primarily cleared
wart areas due to laser therapy duringthe12-week
treatment phase with imiquimod 5% cream and
the six-month treatment-free follow-up. The
target areas (in mm2) were determined before laser
treatment by measuring the width and length of
each wart or cluster of warts, and taking the
product of the two largest perpendicular exten-
sions. Totalwartareawas thesum oftheindividual
warts, or cluster of warts, and was not to exceed
20 cm2. The locations of baseline wart areas were
diagrammed and numbered. Any recurrent warts
and new warts outside the target area were added
to the diagram duringthe controlvisits and clearly
documented as recurrent or new warts.
The safety of imiquimod 5% cream was assessed
by evaluation of local skin reactions and adverse
events at each control visit. Local skin reactions
were assessed by the investigators for erythema,
edema, induration, vesicles, erosion, ulceration,
excoriation/flakingandscabbing.Theseverity was
rated by the study site staff and separately by the
patient on a scale of 0–3 as being 0 = none,
1 = mild, 2 = moderate or 3 = severe. Addition-
ally, patients were asked for adverse events like
itching, burning and pain (application site re-
actions). No additional clinical or laboratory tests
were performed.
All patients who received study medication
were included in the statistical evaluation. With
regard to the design of the study, descriptive statis-
ticalmethodswere used to evaluate all datainclud-
ing demographic and anamnestic data, observed
sustained clearance, safety parameters, other
secondary parameters like patient questionnaire
on previous and actual treatment(s) and compli-
ance. Variables were stratified by gender.
RESULTS
Patient characteristics
Overall, 217 patients were enrolled in the study in
the period January–October 1998, and 211
patients were treated with 5% imiquimod cream
after laser irradiation of their visible anogenital
warts. The patients age ranged from 18–81 years,
with a median age of 32.8 years. Thirty of the 98
male patients(30.6%) were circumcised. Fifty-one
of the 113 female patients (45.1%) used an oral
contraceptive and 121 patients (57.3%; 59 males,
62 females) were current tobacco smokers.
Baseline characteristics of target warts and
history of disease
Female patients presented most frequently with
vulvar condylomata acuminata (87.6%). Male
patients presented with warts on the shaft of the
penis (41.8%) and on the glans penis (19.4%).
Uncircumcisedmales hadwartsassociated withthe
foreskin in 24.5% (external) and 32.7% (internal
surface). The second most common wart location
in both male and female patients was the perianal
region (47.9% males, 39.8% females). The total
wart area ranged from 2 to 2050 mm2 with a
mean of 427 mm2 in male and 256 mm2 in female
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thewartswas15months.Before thepatientscould
participate in the study, all visible warts were
removed by laser treatment; the most frequently
used lasers were the CO2-laser (176 cases),
followed by Nd:YAG-laser in 24 cases, and others
in ten cases.
Before study commenced, patients were asked
to complete a questionnaire regarding their
opinion of their condition and previous treat-
ment(s), if applicable. Most of the patients
(n = 112, 53.1%) reported to have undergone at
least one previous treatment, most often ablative;
74.1% were treated within the last six months, and
now presenting with wart recurrences or new
warts. Treatment was associated with pain in
75.2% of cases; only 29 reported a total regression
of their warts immediately after treatment, and
warts recurred in nearly 40% of all pretreated
patients. Details on previous treatments and
patient experiences are given in Table 1.
Patient accountability and reasons for
withdrawal
Two hundred and twenty-six patients were
screened, and 217 entered the study. Six patients
had to be excluded from the analysis for various
reasons (exclusion criteria (three), phimosis after
laser therapy (one), two patients did not start
treatment). Thus, 211 patients began the topical
imiquimod 5% treatment within 21 days of
laser treatment of their external condylomata
acuminata. Before entering the follow-up period,
73 (34.6%) patients were withdrawn. The most
common reasons for withdrawal were skin irrita-
tion (n = 18, 8.5%), noncompliance (n = 16,
7.6%) and wart recurrences (n = 15, 7.1%).
Twenty-seven of the remaining 138 patients were
excluded during the six-month treatment-free
follow-up period, mainly for noncompliance
(n = 14, 10.1%) and wart recurrence (n = 10,
7.2%). Overall, 111 patients (65 males, 67 females)
completed the clinical trial.
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Total number of patients
Male (%)
(n = 98)
Female (%)
(n = 113)
Total (%)
(n = 211)
Previous treatments*
Patients
Laser
Podophyllin resin
Podophyllotoxin
Electrocautery
Cryotherapy
Trichloracetic acid
Liquid substances (not specified)
Other
*more than one answer possible
58.2
16.3
15.3
13.3
14.3
3.1
1
3.1
2
48.7
18.6
8.8
9.7
5.3
1.8
2.7
6.2
0.9
53.1
17.5
11.8
11.4
9.5
2.4
1.9
4.7
1.4
Wart recurrence
within three month after treatment
> 3 months after treatment
35.1 (n = 20)
60
40
43.6 (n = 24)
70.8
29.2
39.3 (n = 44)
65.9
34.1
Pain 37/53 (69.8) 42/52 (80.8) 79/105 (75.2)
Satisfaction
Very satisfied
Satisfied
Not at all satisfied
(n = 54)
5.6
68.5
25.9
(n = 53)
15.1
56.6
28.3
(n = 107)
10.3
62.6
27.1
Table 1 Previous treatments and patient experiences (patient questionnaire)Sustained clearance: efficacy of imiquimod 5%
cream
Sustained clearance was observed in 138/211
patients (65.4%) until the end of the three-month
treatment period with imiquimod 5% cream. Out
of the 138 patients who entered the follow-up
phase, 111 (80.4%) showed sustained clearance at
the end of the six-month treatment-free follow-
up.A total of 25/211 patients, 15 during the treat-
ment phase and ten during follow-up, developed
recurrent warts in the ablated target wart areas
from the start of the study until the end of the
follow-up period, corresponding to 11.8% of all
patients included in the study. Patients who were
withdrawn prematurely for other reasons than
recurrences (n = 55 during the treatment phase,
n = 20 after the end of treatment) were not
followed and therefore, sustained clearance could
not be evaluated. Due to premature patient with-
drawals,actualpatientnumberswerereducedfrom
month to month (Table 2).
Removing patients lost to follow-up, 153
evaluable patients remained at the end of the three
monthsofimiquimod treatment, 132patientsafter
the first three months of follow-up and 111 at the
end of the six-month follow-up period; the inci-
dences of recurrences related to the number of
evaluable patients are 9.8% (n = 15/153), 7.6%
(n = 10/132) and 0%, respectively. A stepwise
analysis of observed clearance/recurrence rates,
related to actual number of cases at the monthly
control visits during treatment and every three
months during follow up, revealed a consistently
high percentage of patients who remained wart
free for nine months after enrollment in the study
(Figure 1); differences to 100% represent missing
values. The highest number of recurrences (7.6%),
but also the highest percentage of patients with
missing values(9.8%),wasobservedduringthefirst
three months after the end of treatment. Overall,
recurrence rates in male patients were slightly
higherthan in female patients. While on treatment
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Baseline (n = 211)
Imiquimod
4 weeks
Imiquimod
8 weeks
Imiquimod
12 weeks
Follow-up
3 months
Follow-up
6 months
Patients returned
males/females
201
94/107
167
78/89
141
68/73
132
65/67
111
55/56
Patients withdrawn/lost to follow-up 10 34 26 9 21
Table 2 Number of patients returned to monthly control visits during imiquimod 5% treatment and treatment-free
follow-up
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Figure 1 Percentage of observed sustained clearance and recurrence rates during imiquimod 5% cream
treatment and treatment-free follow up (missing values )with imiquimod 5% cream, 12% (9/75) versus
7.7% (6/78) respectively presented recurrent warts
in the target areas, during follow-up the corre-
sponding percentages were 9.2% (6/65) and 6%
(4/67).
New warts outside the treated areas were
observed in 38/201 (18.9%, 18 males, 20 females)
patients during the treatment phase, and another
17/138 (12.3%, 10 males, 7 females) patients
developednewwartsduringthefollow-upperiod.
Compliance and patient questionnaire on
adjuvant treatment with topical imiquimod
There were only minor variations in the patient
compliance rate during the three months of
treatment (83.6%, 79.6% and 88.7% in months
one, two and three, respectively) without signifi-
cant differences related to gender. Patients who
successfully completed the three-month treatment
(n = 138) were asked about their opinion on the
use of adjuvant imiquimod 5% cream. Overall,
89.1% of patients were ‘very satisfied’ or ‘satisfied’
with the treatment. Handling of the cream was
judged as ‘very easy’ or ‘easy’ by 97.1%. Most of
the patients (77.3%) did not lose any working or
school days due to wart treatment. Details are
given in Table 3.
Safety evaluation
No serious adverse events related to study drug
were reported. Adverse events were most often
related to local skin reactions at the treatment site,
andin a few cases, systemic symptoms such asfever
or myalgia were reported. Skin disorders in the
treated wart areas including burning, itching, pain
andrednesswerethemost common adverse effects
and occurred in more than 80% of all patients.
Usually they were well tolerated and rapidly
resolved after reduction of dosing or taking a rest
period.
During the treatment phase, 18 patients (8.5%)
discontinued the study because of skin reactions at
theapplicationsite. Mostofthem reported moder-
atetosevere erythema,burningorpainandmild to
moderate itching.Less frequently,othersymptoms
like edema,erosion,bleeding,scabbing,ticklingor
tenderness were observed. In two cases, patients
developed systemic moderate to severe flu-like
symptoms, whichwere judgedby theinvestigators
to be probably drug-related. One additional
patient discontinued treatment prematurely
because of fever, but had no other adverse events;
in this case a causality to study drug could not
be determined.
As expected, most of the patients (85.3%)
reported generally mild local skin reactions
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Question/statement
Male (%)
(n = 68)
Female (%)
(n = 70)
Total (%)
(n = 138)
Number of missed working/school days
0
1–5
6–10
11–28
don’t know/don’t work
missing values
83.1%
7.4%
1.5%
2.9%
4.5%
4.5%
71.6%
12.9%
2.9%
4.3%
7.1%
4.3%
77.3%
10.2%
2.2%
3.6%
5.8%
4.4%
Ease of use
very easy
easy
difficult/very difficult
66.2%
29.4%
4.5%
51.4%
47.2%
1.4%
58.7%
38.4%
2.9%
Overall satisfaction with study drug
very satisfied
satisfied
not at all satisfied
32.4%
55.9%
11.7%
20%
70%
10%
26.1%
63%
10.9%
Table 3 Results of patient questionnaire: end of three-month treatment with imiquimod 5% creamfollowing laser therapy. After sufficient wound
healing, patients started the imiquimod 5%
treatment.Theywere assessed monthlyforspecific
local skin reactions known to be probably related
to the study drug. During the whole treatment
period,most patientsdid notpresent any objective
skin reaction except for erythema, which was
presentin 60–70% ofcases. Frequencyandseverity
of symptoms was highest during the first month
after laser treatment. In months two and three of
treatment, the skin symptoms improved and the
number of severe reactions decreased (Table 4).
The most common application site reactions
reported by the patients were itching/pruritus
(28.9%), burning (20.9%) and pain (9%). After
the end of treatment, the local application site
symptoms rapidly improved, and after six months
only three patients (2.7%) presented with mild
erythema, induration or erosion.
DISCUSSION
Data in the literature show variable recurrence
rates after laser therapy of genital warts, and recur-
rences develop most frequently in the margins of
previously ablated areas. It has been postulatedthat
the outcome could be improved by extending the
ablation beyond the visible lesion to adjacent,
clinically unaffected regions containing latent
HPV4. However, neither microscopically guided
treatment of acetowhite, subclinical HPV infec-
tion in males, nor CO2 laser vaporization of
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Symptom Severity
Post-laser (%)
(n = 211)
4 weeks (%)
(n = 201)
8 weeks (%)
(n = 167)
12 weeks (%)
(n = 141)
Erythema mild
moderate
severe
49.8
10.4
0
35.8
25.9
9.5
45.5
19.2
8.4
39.7
17
3.5
Erosion mild
moderate
severe
37
17.1
2.4
20.9
9.5
3
21.6
6.6
2.4
15.6
5.7
0.7
Edema mild
moderate
severe
22.7
0.9
0
14.9
8.5
3.5
14.9
8.5
3.5
15.6
0.7
0.7
Ulceration mild
moderate
severe
22.7
9
0.9
8.5
1.5
2
9.0
2.4
0
1.4
2.1
0.7
Vesicles mild
moderate
severe
0.5
0.5
0
0.5
0.5
0
2.4
1.2
0
0.7
0.7
0
Induration mild
moderate
severe
16.1
2.8
0
14.4
3
0
14.4
1.8
0
19.9
0.7
0
Excoriation/flaking mild
moderate
severe
5.7
4.3
2.4
6
6
1
8.4
4.8
0
8.5
2.8
0.7
Scabbing mild
moderate
severe
26.1
3.3
0
12.4
3.5
0.5
9
3
0
5
2.1
0
Table 4 Frequency and severity of observed local skin reactions after laser treatment and during treatment with
imiquimod 5% creamthe entire inferior genital tract in females
demonstrated eradication of the underlying viral
infection or prevention of recurrences11,12. A
different approach through the enhancement of
the cutaneous antiviral immune response is avail-
able through immune response modifiers. The results
of this open-label, prospective study demonstrate
thattheoutcomeoflaser therapyforexternal geni-
tal warts can be sustained by an adjuvant topical
immunomodulatory treatment, imiquimod 5%
cream. In this study, the results of laser therapy
with imiquimod 5% cream were superior to those
oflaser therapyalonedocumentedintheliterature.
Overall, 65.4% of all treated patients remained
wart free after three months of active treatment,
whereas only 7.1% (15/211) presented with wart
recurrences during the treatment period. The
remaining patientswerelost tofollow-upandtheir
outcome is unknown. Furthermore, even the
long-term results seem to be very promising with
recurrences of 7.3% (10/138) duringthefirst three
months of treatment-free follow-up, and no
further recurrences within the following three
months.No effectwas seen on thedevelopmentof
new warts in untreated skin areas observed in
27% (57/211) of patients; this is in accordance
with animal studies which have shown that
topical imiquimod exhibits its immunological
effects exclusively at the application site13.
The reduced recurrence rate with adjuvant
imiquimod 5% cream treatment is likely to be
related to the activation of a local cellular immune
response, which is mediated largely through the
induction of certain pro-inflammatory and anti-
viral cytokines, predominantly IFN-a, tumor
necrosis factor-a (TNF-a) and several inter-
leukines (e.g. IL-6, -8, -10, -12). The mechanism
of action in HPV-related genital warts has been
demonstrated in a molecular study with HPV-
infected patients7. Regression of warts was directly
related to changes in the tissue levels of these
cytokinesandasignificantreductioninviral loadas
measured by tissue levels of E7-mRNA and capsid
protein L1-mRNA. Most interestingly, one of
thestudy subjectstreated with placebo also experi-
enced complete clearance of his warts, and the
changesin immunologicalmarkersdocumentedin
this subject were very similar to those in the
imiquimod-treated patients. This enhancement
of the local immune response also results in a
long-term effect on dermal HPV-infections, with
prevention of recurrences and new infections
with the same HPV type or subtype, comparable
to the immunological process occurring during
spontaneous regression14.
From previousstudies it is knownthatlocalskin
reactions occur frequently, especially during the
first month of treatment with imiquimod 5%
cream and are considered to be due to the local
immune induction and are an essential aspect of
the drug’s antiviral and antitumor activity7–9. In
this study, imiquimod 5% cream was applied
following laser therapy and the incidence of skin
reactions was highest during the first month of
treatment. Wound healing itself is associated with
specific alterationsinskinimmunology.Ithasbeen
demonstrated that during 42 days after surgery
there is a decrease of total T-lymphocytes in the
margins of dermal wounds, associated with an
increase in CD8+ T-suppressor cells and a reduc-
tion of the CD4+/CD8+ T-lymphocyte ratio, and
a concomitant increase in B-lymphocytes15. The
pattern of cytokines evaluated in surgical wounds,
and after thermal injury, revealed elevated local
concentrations of transforming growth factor-ß
(TGF-ß) and pro-inflammatory cytokines like
IL-1, IL-6, IL-8 and TNF-a16–18. The concentra-
tions of the single cytokines varied according to
different steps of wound healing during the obser-
vation periods. However, no long-term studies
have been performed,and the cytokinekinetics or
activity of macrophages two or three weeks after
a thermal injury are still undetermined.
Provided that early inflammation is an impor-
tantfactorinanykindofwoundhealing,including
thermal injury by laser treatment, it was not
surprising to observe an enhanced incidence of
local skin reactions to post-laser therapy with
imiquimod 5% cream which also induces the
expression of certain pro-inflammatory cytokines.
The most frequently reported skin reaction was
erythema in approximately 40% of all patients,
with severe erythema in approximately 10% of
patients. This is comparable to previous results
with imiquimod 5% cream for primary treatment
of external genital warts in uncircumcised males9.
Edema, excoriation/flaking and scabbing were
somewhat more pronounced in laser treated
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imiquimod therapy the incidence of skin reactions
generally returned to levels reported from other
studies.Thisindicatesthatadjuvanttreatment with
imiquimod 5% cream following ablative therapy
should not start unless the wound healing is
apparently completed.
Patients who remained in the study during the
complete treatment course generally were very
satisfied with the combined ablative/adjuvant
treatment. This probably is related to the low
recurrencerate comparedto previous experiences,
better tolerability and simple, self-administered
drug treatment. On the other side, the high drop
out rate is one of the major critical issues of this
study and is most likely due to patients’ reluctance
to follow a three months medical treatment course
after complete ablation of their lesions with no
clinically visible genital warts. To ensure patients
benefit from the therapeutic procedure, they
should be instructed thoroughly on adherence to
the proposed treatment schedule and administra-
tion of the drug only to the area involved, includ-
ing the margins of the ablated area.
The data presented in this study clearly demon-
strate that laser treatment of genital warts followed
by treatment with topical imiquimod 5% cream
over 12 weeks is safe and appears to be an effective
therapeutic approach to reduce the incidence of
wart recurrences, one of the most unsatisfactory
aspects of conventional treatment modalities.
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